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Insulin-like growth factor I (IGF-I) stimulates smooth muscle cell (SMC) proliferation, and the mitogen-activated protein
kinase (MAPK) pathway plays an important role in mediating IGF-I–induced mitogenic signaling. Our prior studies have
shown that recruitment of Src homology 2 domain tyrosine phosphatase (SHP-2) to the membrane scaffolding protein Src
homology 2 domain–containing protein tyrosine phosphatase substrate-1 (SHPS-1) is required for IGF-I–dependent
MAPK activation. The current studies were undertaken to define the upstream signaling components that are required for
IGF-I–stimulated MAPK activation and the role of SHPS-1 in regulating this process. The results show that IGF-I–induced
Shc phosphorylation and its subsequent binding to Grb2 is required for sustained phosphorylation of MAPK and
increased cell proliferation in SMCs. Furthermore, for Shc to be phosphorylated in response to IGF-I requires that Shc
must associate with SHPS-1 and this association is mediated in part by SHP-2. Preincubation of cells with a peptide that
contains a phospho-tyrosine binding motif sequence derived from SHPS-1 inhibited IGF-I–stimulated SHP-2 transfer to
SHPS-1, the association of Shc with SHPS-1, and IGF-I–dependent Shc phosphorylation. Expression of an SHPS-1 mutant
that did not bind to Shc or SHP-2 resulted in decreased Shc and MAPK phosphorylation in response to IGF-I. In addition,
SMCs expressing a mutant form of the 3 subunit of the V3, which results in impairment of SHP-2 transfer to SHPS-1,
also showed attenuated IGF-I–dependent Shc and MAPK phosphorylation. Further analysis showed that Shc and SHP-2
can be coimmunoprecipitated after IGF-I stimulation. A cell-permeable peptide that contained a polyproline sequence
from Shc selectively inhibited Shc/SHP-2 association and impaired Shc but not SHP-2 binding to SHPS-1. Exposure to this
peptide also inhibited IGF-I–stimulated Shc and MAPK phosphorylation. Cells expressing a mutant form of Shc with the
four prolines substituted with alanines showed no Shc/SHPS-1 association in response to IGF-I. We conclude that SHPS-1
functions as an anchor protein that recruits both Shc and SHP-2 and that their recruitment is necessary for IGF-I–
dependent Shc phosphorylation, which is required for an optimal mitogenic response in SMCs.
INTRODUCTION
Both vascular smooth muscle cell proliferation and migra-
tion in response to growth factor stimulation play important
roles in the formation of atherosclerotic plaques, and insu-
lin-like growth factor I (IGF-I) is a potent stimulator of
smooth muscle cell proliferation and migration (Jones et al.,
1996). In primary cultured smooth muscle cells (pSMCs),
IGF-I induces activation of both the phosphatidylinositol
(PI)-3 kinase and the mitogen-activated protein (MAP) ki-
nase (MAPK) pathways. Both pathways have been shown to
play roles in mediating IGF-I–dependent cell migration and
cell proliferation responses (Imai and Clemmons, 1999;
Maile et al., 2003).
Previous studies have shown that the protein tyrosine
phosphatase SHP-2 plays an important role in mediating
growth factor-mediated mitogenic signaling (Noguchi et al.,
1994; Bennett et al., 1996; Maroun et al., 2000; Cai et al., 2002;
Neel et al., 2003). The catalytic activity of SHP-2 and its
recruitment to signaling molecules such as Grb2-associated
binder 1 (Gab1) are required for full activation of the MAP
kinase pathway in response to epidermal growth factor
(EGF) (Holgado-Madruga et al., 1996; Schaeper et al., 2000;
Shi et al., 2000; Cai et al., 2002). SHP-2 phosphatase activity
also has been shown to be required for insulin to activate
MAP kinase in chinese hamster ovary (CHO) cells (Noguchi
et al., 1994).
Src homology 2 domain containing protein tyrosine phos-
phatase substrate-1 (SHPS-1) is a transmembrane protein
that plays an important role in mediating various cellular
responses, including migration and proliferation. The cyto-
plasmic domain of SHPS-1 contains four tyrosine residues
located within YXXL/I/V motifs that can undergo phos-
phorylation after growth factor stimulation or cell adhesion
and then bind to SH-2 domain containing proteins such as
SHP-2 (Fujioka et al., 1996; Takada et al., 1998; Oh et al., 1999).
Transfer of SHP-2 to SHPS-1 is required for growth factor-
mediated cell proliferation, DNA synthesis, and MAP kinase
activation (Takada et al., 1998; Ling et al., 2003; Maile et al.,
2003). Disruption of SHP-2 binding to SHPS-1 either by
expressing a SHPS-1 mutant that does not bind SHP-2
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(Takada et al., 1998) or by inhibiting SHPS-1 phosphoryla-
tion (Maile et al., 2003) leads to impairment of sustained
MAP kinase activation. In SMCs, SHP-2 is basally associated
with the tyrosine-phosphorylated 3 subunit of the V3
integrin (Ling et al., 2003). IGF-I stimulation induces the
phosphorylation of SHPS-1 and the subsequent binding of
SHP-2 to SHPS-1 (Maile and Clemmons, 2002). Inhibition of
3 or SHPS-1 phosphorylation leads to impaired SHP-2
transfer to SHPS-1 in response to IGF-I, and this correlates
with a reduction in the cellular DNA synthesis response
(Ling et al., 2003; Maile et al., 2003). Although it is clear that
SHP-2 transfer to SHPS-1 plays an important role in medi-
ating IGF-I–dependent cellular proliferation, the mechanism
by which SHP-2 association with SHPS-1 regulates MAP
kinase activation has not been determined.
Tyrosine phosphorylation of adaptor proteins such as
IRS-1 and Shc acts to link the activated IGF-I receptor with
downstream signaling elements in the PI-3 and/or MAP
kinase pathways. In many cell types such as neurons, fibro-
blasts, and adipocytes, phosphorylation of Shc and its asso-
ciation with the adaptor protein Grb2 are required for
growth factor-mediated mitogenic signaling (Kim et al.,
1998; Boney et al., 2000; Sasaoka et al., 2001). In pSMCs, IGF-I
stimulation induces tyrosine phosphorylation of IRS-1 fol-
lowed by its association with the regulatory subunit of PI-3
kinase (p85), which leads to activation of the PI-3 kinase
pathway (Zheng and Clemmons, 1998). However, it remains
unclear whether phosphorylation of Shc mediates IGF-I–
stimulated responses in pSMCs; in particular, the role of Shc
in mediating IGF-I–dependent mitogenic signaling has not
been determined.
The current study was undertaken to determine whether
Shc activation was required for sustained MAP kinase acti-
vation in response to IGF-I in cultured SMCs, to determine
whether Shc binding to SHPS-1 played a role in IGF-I–
dependent Shc phosphorylation and whether SHP-2 played
a role in their association.
MATERIALS AND METHODS
Human IGF-I was a gift from Genentech (South San Francisco, CA). Immo-
bilon-P membranes were purchased from Millipore (Bedford, MA). DMEM
containing 4500 mg glucose/l (DMEM-H) was purchased from Invitrogen
(Carlsbad, CA), and streptomycin and penicillin were purchased from In-
vitrogen. A polyclonal antibody for the 3-subunit of porcine V3 integrin
was generated using two synthetic peptides containing the amino acid se-
quences encompassing positions 36–63 and 623–648. A polyclonal antibody
for SHP-2 was generated using peptides that contained the SHP-2 sequences
corresponding to amino acid 367–387 and 486–497. Polyclonal antibodies for
IRS-1, SHPS-1, and the hemagglutinin (HA) epitope were obtained from
Upstate Biotechnology (Lake Placid, NY). The anti-phospho-tyrosine (p-Tyr)
antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against phospho-extracellular signal-regulated kinase (Erk)1,2,
total Erk1,2, Shc, and Grb2 were from BD Transduction Laboratories (Lex-
ington, KY). EZ-link Sulfo NHS SS biotin was purchased from Pierce Chem-
ical (Rockford, IL). Synthetic peptides that contained the TAT cell-permeable
sequence (Ho et al., 2001) followed by either an SHPS-1 sequence (under-
lined) YARAAARQARA466TLTYADLDM473 or the proline-rich region of
Shc sequence (underlined) YARAAARQARA358LRVPPPPQSM367 were
prepared. The tyrosine motif control peptide contained the TAT sequence
followed by the Tyr-containing motif (YXXL/I) of p85 (underlined)
YARAAARQARA555EYREIDKR562. The proline-rich control peptide con-
tained the proline-rich region from downstream of kinase 1 (DOK1) (un-
derlined), YARAAARQARA425PQGPAFPEPG434. The peptides were syn-
thesized by the Protein Chemistry Core Facility at the University of North
Carolina at Chapel Hill. Purity and sequence confirmation were deter-
mined by mass spectrometry. [32P]orthophosphoric acid (8000 –9200 Ci/
mmol) was purchased from Amersham Biosciences (Piscataway, NJ).
Cell Culture
pSMCs were prepared from porcine aortas as described previously (Parker et
al., 1995). Cells were maintained in DMEM-H with 10% fetal bovine serum
(FBS) (Hyclone Laboratories, Logan, UT), streptomycin (100 g/ml), and
penicillin (100 U/ml). pSMCs that were used in these experiments were used
between passages 4 and 16.
Generation of pMEP4-Expression Vectors and
Establishment of Vector Control and 3-FF Cells
A full-length cDNA encoding a mutant form of human 3 integrin subunit
containing two substitutions Y747F and Y759F (3-FF) was generated in the
pMEP4 expression vector as described previously (Ling et al., 2003). The
construct contains a FLAG epitope sequence (DYKDDDDK) inserted between
the leader sequence and mature protein sequence. Cells that had been trans-
fected with the pMEP4-vector that did not contain 3-FF insert were used as
control. pSMCs (passages 4 and 5) were transfected with these constructs by
using the poly-l-ornithine method as described previously (Parker et al., 1995;
Ling et al., 2003). The cells were maintained in DMEM-H with 15% FBS and
40 g/ml hygromycin plus streptomycin and penicillin. The cells that were
used in these experiments were between passages 6 and 15.
Generation of Plenti-Expression Vectors
pLenti-HA-p52Shc/WT (Wild-Type Shc) and pLenti-HA-p52Shc/3F. (Shc/
Y239/240/317F) pcDNA-p52Shc/WT and pcDNA-p52Shc/3F constructs
were kindly provided by Dr. Kenneth Yamada (NIH, Bethesda, MD). Muta-
tion of these three tyrosine phosphorylation sites has been shown to generate
a dominant negative inhibitor of Shc signaling (Kim et al., 1998). Full-length
Shc/WT and Shc/3F were PCR amplified using the following forward and
reverse primers: 5-CACCATGTACCCATACGATGTTCCAGAT-
TACGCTAACAAGCTGAGTGGAGGCGGCGGG-3 and 5-TTACAGTTTC-
CGCTCCACAGGTTGCTG-3. The PCR products containing a Kozak se-
quence (CACC) followed by a sequence encoding the HA epitope
(underlined) at the 5 end of the p52 Shc coding sequence were cloned into the
plenti6/V5-D-TOPO expression vector (Invitrogen, Carlsbad, CA). The com-
plete sequence was verified by DNA sequencing.
pLenti-Shc4A. Human p52Shc cDNA was cloned in to pENTR/D-TOPO
Gateway entry vector according to the manufacturer’s instructions (Invitro-
gen). Wild-type sequences were transferred to plentiCMV Gateway by LR
clonase reaction and transformed into Stbl3 competent cells (Invitrogen).
Incorporation of the p52 Shc DNA sequence was verified by restriction digest
with EcoRV. Amino acids 361–364 were changed from prolines to alanines by
double-stranded mutagenesis of pENTRp52Shc. One hundred and twenty-
five nanograms of complimentary oligonucleotides was annealed to 50 ng of
supercoiled plasmid and extended by linear PCR amplification by using Pfx
polymerase (Invitrogen). The oligonucleotide sequences were 5-gaagatgctct-
tcgggtgGctGcaGctGcccagtcggtgtccatg-3 forward and 5-catggacaccgact-
gggCagCtgCagCcacccgaagagcatcttc-3 reverse, where the capitalized bases
indicate the substitutions. The resulting plasmids were digested by DpnI
(New England Biolabs, Beverly, MA) and transformed into TOP10 competent
cells (Invitrogen). The cells were plated and colonies isolated. Correct incor-
poration of the changes was confirmed by DNA sequencing (UNC Genome
Analysis Facility, Chapel Hill, NC)
pLenti-HA-SHPS-1/WT and pLenti-HA-SHPS-1/-CD. Full-length human
SHPS-1 cDNA was generated by reverse transcription-PCR from mRNA that
had been derived from human fibroblasts (GM10; Human Genetic Cell Re-
pository, Camden, NJ) (Maile and Clemmons, 2002). The full-length SHPS-1
sequence was PCR amplified using previously generated pcDNA-SHPS-1
(Maile and Clemmons, 2002) as a template and cloned into the expression
vector plenti6/V5-D-TOPO. The forward and reverse primers used to gener-
ate the PCR product were 5-CACCATGGAGCCCGCCGGCCCGGC-3 and
5-TTAAGCGTAATCTGGAACATCGTATGGGTACTTCCTCGGGACCTG-
GACGCT-3. The wild-type SHPS-1 construct contains an HA sequence at the
3 end of the coding sequence (underlined). The SHPS-1 coding sequence was
truncated at K398, producing a truncated SHPS-1 mutant (SHPS-1/-CD) that
contains only the first five residues (amino acids 394–398) of the 110 residues
(394–503) within the cytoplasmic domain. The truncated SHPS-1 was gener-
ated by PCR amplification with Stratagene (La Jolla, CA) Pfu Turbo polymer-
ase by using forward and reverse primers as follows: 5-CACCATGGAGC-
CCGCCGGCCCGGC-3 and 5-TTAAGCGTAATCTGGAACATCGT-
ATGGGTACTTCTGTCTGATTCGGACGAGGTAGA-3. The PCR product
containing the underlined HA sequence at the 3 end of the SHPS-1 mutant
coding sequence was TOPO-cloned into the plenti6/V5-D-TOPO expression
vector. The SHPS-1/-CD sequence was confirmed by DNA sequencing.
Generation of Virus Stocks
293FT cells (Invitrogen) were prepared for generation of virus stocks of each
individual plenti-construct. Cells were plated at 5  106 per 75-cm2 plate
(Corning Glassworks, Corning, NY) the day before transfection in the growth
medium (DMEM-H with 10% FBS with streptomycin at 100 g/ml and
penicillin at 100 U/ml). On the day of transfection, the culture medium was
replaced with 5 ml of Opti-MEM-I (Invitrogen) without antibiotics or serum.
DNA–Lipofectamine 2000 complexes for each transfection sample were pre-
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pared according to the manufacturer’s protocol (Invitrogen). The next day,
the medium containing the DNA–Lipofectamine 2000 complexes was re-
moved and replaced with the growth medium. The virus-containing super-
natants were harvested 48–72 h posttransfection and centrifuged at 3000 rpm
for 15 min at 4°C to pellet the cell debris. The supernatants were filtered and
stored as 1-ml aliquots at –80°C.
Establishment of SMCs Expressing pLenti-Vector Control
and pLenti-Constructs
pSMCs (passages 4 and 5) were seeded at 3  105/well in each of two wells
of a six-well plate (353046; Falcon; BD Biosciences Discovery Labware, Bed-
ford, MA) the day before transduction. The viral stocks were thawed, and the
viral complexes precipitated as follows. For each 1 ml of virus stock, 1 l of
an 80 mg/ml solution of chondroitin sulfate (C4384; Sigma-Aldrich, St. Louis,
MO) was added and then mixed gently and incubated at 37°C for 10 min. One
microliter of 80 mg/ml polybrene (H9286; Sigma-Aldrich) was added and
incubated at 37°C for 10 min. The mixture was centrifuged at 10,000 rpm for
5 min to pellet virus, and the supernatant was removed. For transduction, the
pellet was resuspended in 1 ml of growth medium, and 1 l of 40 mg/ml
polybrene was added and then the mixture was incubated with the cells for
24 h. The virus-containing medium was removed and changed to 2 ml of
growth medium for another 24 h and then replaced with selection medium
(growth medium containing 4 g/ml blasticidin). The cultures were then
grown to confluence.
The expression of HA-tagged p52Shc protein was detected by immunoblot-
ting with a 1:1000 dilution of anti-HA antibody using 30 l of cell lysate.
Detection of Cell Surface Protein Expression
Cells expressing plenti-SHPS-1 constructs were grown to confluence, and the
cell surface proteins were biotinylated as described previously (Maile et al.,
2001). The cultures were then lysed and an equal amount of protein from each
cell lysate was immunoprecipitated using the anti-HA antibody. The immune
complexes were then separated by 7.5% SDS-PAGE under nonreducing con-
ditions. Biotinylated SHPS-1 was detected by immunoblotting with peroxi-
dase-conjugated avidin as described below.
Immunoprecipitation and Immunoblotting
Cells were seeded at 5  105 cells per 10-cm plate (BD Biosciences, Franklin
Lakes, NJ) and grown for 7 d to reach confluence. The cultures were incubated
in serum-free DMEM-H for 12–16 h before the addition of 100 ng/ml IGF-I.
For the experiments in which the cell-permeable peptides were added, 10 or
20 g/ml of each peptide was added directly to serum-free medium for 1 h
before adding IGF-I. The cell monolayers were lysed in a modified radioim-
munoprecipitation assay (RIPA) buffer (1% Nonidet P-40, 0.25% sodium
deoxycholate, 1 mM EGTA, 150 mM NaCl, and 50 mM Tris-HCl, pH 7.5) in
the presence of protease inhibitors (10 g/ml aprotinin, 1 g/ml leupeptin, 1
mM phenylmethylsulfonyl fluoride, and 1 g/ml pepstatin), and phospha-
tase inhibitors (25 mM sodium fluoride and 2 mM sodium orthovanadate).
The cell lysates were centrifuged at 14,000  g for 10 min at 4°C. The
supernatant containing crude membrane and cytosolic proteins was exposed
to a 1:330 dilution of anti-IRS-1, anti-Shc, anti-HA, anti-3, or anti-SHPS-1
antibodies overnight at 4°C. The immunoprecipitates were immobilized using
protein A beads for 2 h at 4°C and washed three times with the same lysis
buffer. The precipitated proteins were eluted in 40 l of 2 Laemmli sample
buffer, boiled for 5 min, and separated on a 7.5, 8, or 12.5% SDS-PAG. For
detection of 3/Shc association and SHP-2/Shc association, the anti-3 anti-
body or anti-Shc antibody was used to immunoprecipitate 3 or Shc. After the
first round of immunoprecipitation, the supernatant was used for a second
round of immunoprecipitation with the same antibodies. Both immunopre-
cipitates were combined and loaded on 8% SDS-PAG. Further analysis
showed that after two rounds of immunoprecipitation 95% of the total
amount of either 3 or Shc protein that could be detected by immunoblotting
was recovered. The proteins were then transferred to Immobilon-P mem-
branes that were blocked for 1 h in 1% bovine serum albumin in Tris-saline
buffer with 0.2% Tween 20. The blots were incubated overnight at 4°C with
indicated antibodies (1:500 for p-Tyr; 1:1000 for antibodies against HA,
SHPS-1, SHP-2, IRS-1, and Shc; and 1:2000 for anti-Grb2). The levels of 3
protein, Shc, and SHPS-1 that were expressed by each cell type were evalu-
ated by direct immunoblotting of 30 l of cell lysate by using a 1:1000 dilution
of anti-3 antibody, polyclonal anti-Shc or anti-SHPS-1 antibody. To detect
Erk1,2 activation, 30 l of cell lysate was removed before immunoprecipita-
tion and mixed with 25 l of 2 Laemmli sample buffer then separated by 8%
SDS-PAGE. Anti-phospho-Erk1,2 (1:1000) was used to detect phosphorylated
Erk1,2, and total Erk1,2 protein was detected using a monoclonal anti-Erk1,2
antibody (1:1000). The proteins were detected using enhanced chemilumines-
cence (Pierce Biotechnology, Rockford, IL), and their relative abundance was
analyzed using the GeneGnome charge-coupled device image system (Syn-
gene, Cambridge, United Kingdom). The images obtained were also scanned
using an Agfa (Ridgefield Park, NJ) scanner. Densitometric analyses of the
images were determined using NIH Image, version 1.61. All experiments
were performed at least three times. To correct for gel loading differences and
differences in the efficiency of immunoprecipitation, the results are expressed
as the scanning units divided by the scanning units obtained when the protein
that was immunoprecipitated was quantified by immunoblotting.
Concentration of Cell Lysates
pSMCs were serum starved overnight. The cells were scraped off the plates
into 900 l of phosphate-buffered saline that contained protease and phos-
phatase inhibitors as described above. The samples were frozen and thawed
three times before they were centrifuged at 14,000  g for 10 min at 4°C. The
supernatant was then concentrated using Millipore Ultrafree-0.5 centrifugal
filter device (Millipore, Billerica, MA). After the cell lysate was concentrated
to 100 l, 0.1 ml of in vitro kinase reaction buffer (RB; 100 mM Tris-HCl, pH
7.2, 125 mM MgCl2, 25 mM MnCl2, 2 mM EGTA, 250 M sodium orthovana-
date, and 2 mM dithiothreitol [DTT]) was added, and the samples were
further concentrated to 100 l. The buffer exchange and concentration steps
were repeated one time to a final volume of 100 l.
Detection of Phosphorylation of the SHPS-1 Peptide
In Vivo
Confluent cultures were serum starved overnight. The cultures were incu-
bated for total 3 h in 5 ml of phosphate-free Eagle’s minimal essential medium
containing 250 Ci of [32P]orthophosphate. The SHPS-1 cell-permeable pep-
tide was added for 30 or 60 min at 10 g/ml concentration before cells lysed
in RIPA buffer. Control cultures were exposed to no peptide or a peptide that
does not contain tyrosine residues. The anti-pTyr antibody (1:330) was incu-
bated with the cell lysates and the immunoprecipitation was performed as
described above. After washing the protein A beads three times the precipi-
tated proteins were eluted in 40 l of 2 Laemmli sample buffer and loaded
on to 15% SDS-PAG. A duplicate sample of the SHPS-1 peptide that had been
labeled with 125I (Markwell, 1982) was used as a marker and run in a parallel
lane on the same gel.
Cell Proliferation Assay
Assessment of SMC proliferation was performed as described previously
(Nam et al., 2000). Cells were incubated with or without IGF-I (50 ng/ml) in
serum-free DMEM containing 0.2% platelet-poor plasma for 48 h, and cell
number in each well was counted. Each treatment was analyzed in triplicate,
and the results represent mean values of three independent experiments.
Statistical Analysis
Student’s t test was used to compare the differences between control and
treatment groups or control cells and cells expressing mutant proteins. p 
0.05 was considered statistically significant.
RESULTS
Shc Phosphorylation Is Required for IGF-I–dependent
Mitogenesis in Cultured pSMCs
To determine the necessity for Shc tyrosine phosphorylation
for IGF-I–dependent mitogenic signaling, we generated
pSMCs expressing a control vector, wild-type p52-Shc (Shc-
WT), or p52-Shc with three tyrosine residues (Y239, Y240,
and Y317) that had been mutated to phenylalanine (Shc-3F)
(Kim et al., 1998). p52Shc-WT and p52Shc-3F were overex-
pressed in SMCs, and the levels of exogenous Shc were
comparable as shown in Figure 1A. There was no significant
difference in basal Shc phosphorylation when the Shc-WT–
and Shc-3F–expressing cells were compared (p  NS). IGF-I
induced a 4.2  0.7 (mean  SEM, n  3, p  0.01)-fold
increase in p52Shc phosphorylation after 5 min in cells ex-
pressing Shc-WT, and the maximum level of phosphoryla-
tion was sustained for 20 min (4.0  0.7-fold increase, p 
0.01) (Figure 1B). This correlated with increased Grb2 bind-
ing to phosphorylated Shc-WT, which also was sustained for
20 min (4.5  1.7-fold increase at 5 min, p  0.01 and 3.6 
1.4-fold increase at 20 min, p  0.05, n  3). In contrast,
when the cells expressing Shc 3F were analyzed, there was a
significant reduction in p52-Shc phosphorylation (57.6  7.4
and 68.2  5.6% reductions compared with the control cul-
tures at 5 and 20 min, n  3, p  0.01) and decreased
association of Grb2 (84.2  2.2 and 77.3  5.1% reductions at
5 and 20 min, p  0.05) after IGF-I stimulation. Comparison
of the time course of Erk1,2 phosphorylation showed that
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Erk phosphorylation peaked after 10 min and was detectable
up to 60 min in cells expressing Shc-WT. However, in cells
expressing Shc-3F, this enhanced phosphorylation in re-
sponse to IGF-I was significantly decreased at 10 min (47.5 
18.8% reduction, n  3, p  0.05) and at the later time points
(Figure 1, C and D). There were no significant differences
between the two groups basally or at the 5-min time point,
indicating the change in Shc phosphorylation correlates with
Figure 1. Phosphorylation of Shc mediates IGF-I–dependent mitogenic signaling in SMCs. (A) SMCs expressing wild-type Shc (Shc-WT),
tyrosine-mutated Shc (Shc-3F), or vector control were serum starved overnight and analyzed for recombinant protein expression. Thirty
microliters of cell lysate was immunoblotted using an anti-HA antibody (top). Separate samples were immunoblotted with a polyclonal
anti-Shc antibody to compare the expression levels of total p52Shc in the Shc-transduced cells to vector transduced cells (bottom). (B) SMCs
expressing either Shc-WT or Shc-3F were serum deprived for 12–16 h. After IGF-I stimulation for indicated times, cell lysates were
immunoprecipitated with an anti-Shc antibody and immunoblotted with p-Tyr (top) followed by reprobing with anti-Shc (bottom). Grb2
association was detected by immunoblotting with an anti-Grb2 antibody after Shc immunoprecipitation (middle). Densitometric scanning
units of phospho-Shc and Grb2 were divided by the mean value of total Shc protein that was immunoprecipitated in three experiments and
the results are expressed as arbitrary scanning units  SEM (n  3). The values for phospho-Shc are 154  35, 618  66, 579  27, 207  60,
256  20, and 185  37. The values for Shc associated Grb2 are 203  63, 784  117, 621  103, 148  39, 124  18, and 147  58. (C) Cells
were serum starved then stimulated with IGF-I for indicated times. Thirty microliters of cell lysate was used for detection of phospho-Erk1,2
by immunoblotting with anti-phospho-Erk1,2 antibody. The blots were stripped and reprobed with anti-Erk1,2 antibody. (D) The phosphor-
ylation of Erk1,2 normalized by the protein levels was quantified using scanning densitometry. Each point is the mean  SEM of three
separate experiments. *p  0.05 and **p  0.01 when cells expressing Shc-3F were compared with Shc-WT–expressing cells. (E) The cell
proliferation assay was conducted as described in Materials and Methods. **p  0.01 when treatment with 50 ng/ml IGF-I is compared with
basal state in cells expressing Shc-WT or Shc-3F. (F) IGF-I–induced Shc phosphorylation and Shc binding to Grb2 as well as phosphorylation
of Erk1,2 in vector and in Shc-3F–expressing cells are shown. Densitometric units (n  3) for phospho-Shc divided by total Shc protein
immunoprecipitated are 487  47 and 1695  408 in vector control and 199  99 and 269  96 in Shc-3F–expressing cells. The units for Shc
associated Grb2 binding are 411  114 and 1100  243 in the control and 209  90 and 218  93 in Shc-3F–expressing cells. The units for
phospho-Erk divided by total Erk in control cells are 188  41 and 1329  80 and 216  36 and 253  65 in Shc-3F–expressing cells.
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a change in the sustained phase of Erk1,2 activation. The
residual levels of Erk1,2 phosphorylation in Shc-3F cells
could be due to incomplete inhibition of endogenous Shc
phosphorylation or due to an alternative Erk activation
pathway that does not involve Shc. IGF-I stimulated a 2.3 
1.2 (n  3, p  0.01)-fold increase in cell proliferation in
Shc-WT cells, but this was significantly decreased in cells
expressing Shc-3F (1.1  0.1-fold increase, n  3, p  NS)
(Figure 1E). To control for excess expression of Shc the
results obtained using cells expressing Shc-3F also were
compared with cells that had been transfected with vector
alone. IGF-I induced a 3.4  0.6-fold increase in Shc phos-
phorylation at 20 min and a 2.7  0.3-fold increase in Grb2
binding (n  3, p  0.05) in the cells transduced with vector
alone. However, cells expressing Shc-3F showed impaired
IGF-I induced Shc phosphorylation (1.5  0.2-fold increase
compared with control cultures, n  3, P  NS) and de-
creased Shc binding to Grb2 (1.1  0.4, n  3, p  NS).
Correspondingly, IGF-I–induced Erk1,2 phosphorylation
was significantly reduced (81.1  4.3% compared with vec-
tor expressing cells, n  3, p  0.01) in Shc-3F–expressing
cells (Figure 1F). These results demonstrate that IGF-I–in-
duced Shc phosphorylation and its association with Grb2 are
required for sustained MAP kinase activation and cell pro-
liferation in cultured pSMCs.
Inhibition of 3 Phosphorylation Impairs
IGF-I–dependent Shc and MAPK Activation
We have previously shown that inhibition of 3 phosphor-
ylation led to inhibition of IGF-I–stimulated DNA synthesis
(Ling et al., 2003), a MAP kinase-dependent event (Imai and
Clemmons, 1999). Therefore, we used cells that expressed a
mutant form of 3 that could not be phosphorylated to
determine whether this change would alter the ability of
IGF-I to stimulate both Shc phosphorylation and activation
of MAP kinase. Confluent cultures expressing the pMEP4
vector alone had detectible basal tyrosine phosphorylation
of the 3 subunit, but cells expressing the 3-FF mutant
showed decreased 3 phosphorylation despite the similar
levels of expression of total 3 protein (Figure 2A). Similar to
SMCs expressing wild-type Shc, IGF-I induced tyrosine
phosphorylation of p52-Shc at 5 min (3.5  0.7-fold increase
compared with basal, n  3, p  0.05), and this phosphor-
ylation was sustained up to 20 min in pMEP4-vector–ex-
pressing cells. This response was associated with enhanced
Grb2/Shc association (2.1  0.2-fold increase at 5 min, n 
3, p  0.05). In cells expressing the 3-FF mutant, however,
IGF-I–induced Shc phosphorylation was reduced by 85.4 
6.5% (n  3, p  0.05) at 5 min, and Grb2 association with
Shc in response to IGF-I also was reduced (79.3  9.2%
decrease compared with control, n  3, p  0.05), despite the
fact that comparable amount of Shc was immunoprecipi-
tated (Figure 2B). The significant reduction in both p52Shc
phosphorylation and Grb2 binding was sustained to 20 min
in these cells. The IRS-1 phosphorylation response also was
analyzed. After IGF-I addition, IRS-1 phosphorylation was
increased 7.5  1.0-fold (n  3, p  0.01) at 5 min in
vector-transfected control cells. In contrast to Shc, IRS-1
phosphorylation was not impaired at 5 min (6.9  1.7-fold
increase compared with the basal, n  3, p  0.01), and its
phosphorylation was sustained in cells expressing the 3-FF
mutant. Correspondingly, there was increased Grb2 associ-
ation with phosphorylated IRS-1 in response to IGF-I in both
control and mutant cells (Figure 2C). The IRS-1 protein level
was similar between control and 3-FF–expressing cells.
Despite the sustained phosphorylation of IRS-1, there was a
lack of sustained phosphorylation of Erk1,2 in response to
IGF-I in cells expressing 3-FF mutant (Figure 2, D and E).
Together, these results confirm that Shc but not IRS-1 phos-
phorylation plays a significant role in mediating IGF-I–in-
duced sustained MAP kinase activation in SMCs.
Recruitment of Shc to SHPS-1 but Not to 3 Is Required
for IGF-I–dependent Shc Phosphorylation
Recruitment of Shc to specific membrane compartments is
required for its subsequent phosphorylation upon growth
factor stimulation (Di Guglielmo et al., 1994; Chow et al.,
1998; Sato et al., 2000; Biedi et al., 2003). Integrin ligand
occupancy can facilitate Shc recruitment to the cell mem-
brane, thereby contributing to Shc phosphorylation via di-
rect binding of Shc to phosphorylated  subunits (Cowan et
al., 2000; Dans et al., 2001; Phillips et al., 2001b). Because we
had shown that Shc phosphorylation was impaired in cells
expressing the 3 FF mutant, we determined whether 3
and Shc could be coimmunoprecipitated in response to
IGF-I. Sequential immunoprecipitation was performed to
ensure that most of the 3 protein was depleted from the cell
lysates (Figure 3A). As shown in Figure 3A, Shc was not
associated with 3 either basally or after IGF-I stimulation in
stably attached, nontransfected SMCs.
Several studies have shown that the transmembrane pro-
tein SHPS-1 can recruit signaling molecules to the plasma
membrane (Fujioka et al., 1996; Oh et al., 1999), and our
studies have shown that SHPS-1 phosphorylation is re-
quired for MAP kinase activation (Maile et al., 2003); there-
fore, we determined whether SHPS-1 could recruit Shc in
response to IGF-I. To determine the effect of loss of Shc
binding to SHPS-1, we expressed a mutant form of SHPS-1
that lacks most of the cytoplasmic domain (SHPS-1/-CD).
SHPS-1/WT was expressed at high level compared with
endogenous levels of SHPS-1 (Figure 3B). Cell surface ex-
pression of SHPS-1/-CD was comparable with control cells
that expressed wild-type SHPS-1 (SHPS-1/WT) (Figure 3B).
When the cells expressing SHPS-1/WT were analyzed, IGF-I
stimulated a 5.5  0.9 (mean  SEM, n  4)-fold increase in
Shc association with SHPS-1 after 5 min. In contrast, there
was no detectable SHPS-1/-CD in Shc immunoprecipitates
when cells expressing SHPS-1/-CD were analyzed (Figure
3C). Expression of SHPS-1/-CD in these cells did not signif-
icantly change levels of basal Shc phosphorylation (p  NS)
and its association with Grb2 (P  NS) compared with cells
expressing SHPS-1/WT. IGF-I induced significant increases
in Shc phosphorylation at 5 min (1.9  0.3-fold increase, n 
3, p  0.01) and 10 min (2.2  0.3-fold increase, p  0.05) in
SHPS-1/WT cells (Figure 3D). This correlated with in-
creased Grb2 binding to Shc (2.8  0.3-fold increase at 5 min,
p  0.01 and 2.9  0.4-fold increase at 10 min, p  0.01). In
contrast, IGF-I failed to induce significant increases in Shc
phosphorylation and Grb2 binding in cells expressing SHPS-
1/-CD (p  NS, n  3 for both Shc phosphorylation and
Grb2 binding to Shc) (Figure 3D). IGF-I–induced Erk1,2
phosphorylation was significantly impaired after 10 and 20
min in these cells (Figure 3, E and F). These results suggested
that the SHPS-1 cytoplasmic domain is required for IGF-I–
mediated mitogenic signaling in SMCs.
SHP-2 Association with SHPS-1 Is Necessary for Shc
Phosphorylation and for Shc Association with SHPS-1
Several previous studies have shown that the tyrosine phos-
phatase SHP-2 is transferred to SHPS-1 in response to mito-
gens, and in some cases, this has been shown to be required
for a mitogenic response (Fujioka et al., 1996; Takada et al.,
1998). In cells expressing the 3-FF mutant, SHPS-1 was
phosphorylated in response to IGF-I, but the transfer of
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SHP-2 to SHPS-1 was impaired (Ling et al., 2003). This raised
the possibility that in cells expressing 3 FF, wherein SHP-2
transfer to SHPS-1 is blocked, SHP-2 transfer is necessary for
either Shc binding or for its phosphorylation. Therefore, we
used cells expressing the 3 FF mutant to determine whether
inhibition of SHP-2 transfer to SHPS-1 was associated with
loss of Shc binding. In control cultures expressing the pMEP
4 vector alone, IGF-I induced a 3.2  0.8 (n  3, p 
0.05)-fold increase in Shc and SHPS-1 coprecipitation (Figure
4A) after 5 min. However, in cells expressing the 3-FF
mutant Shc binding to SHPS-1 was reduced 86.2  2.1%
compared with control cultures (n  3, p  0.01) (Figure
4A), and this was associated with an inhibition of Shc phos-
phorylation (Figure 2B). Because in cells expressing both 3
FF and SHPS-1/-CD, SHP-2 transfer to SHPS-1 (Ling et al.,
2003), Shc recruitment to SHPS-1, and Shc phosphorylation
are impaired, this argues strongly for a role for SHP-2 in
mediating Shc binding to SHPS-1 and therefore Shc phos-
phorylation.
To determine directly whether SHP-2 binding to SHPS-1
was necessary for Shc recruitment and phosphorylation, we
used a cell-permeable peptide homologous to the site within
the SHPS-1 cytoplasmic domain that binds directly to SHP-2
(Takada et al., 1998). We predicted that this peptide would
bind to SHP-2 and prevent it from binding to SHPS-1,
thereby allowing us to examine the role of SHP-2 in medi-
ating Shc binding in nontransfected cells. Because SHP-2
binding to SHPS-1 requires phosphorylation of tyrosine res-
idues within this peptide sequence, we incubated the pep-
tide with SMC cultures as described in Materials and Meth-
ods. After 30 min, phosphorylation of the peptide was
detected as indicated by incorporation of 32P-orthophos-
phate (our unpublished data). In contrast to control cultures
in which IGF-I induced SHP-2 transfer to SHPS-1 after 5
min, exposure to 20 g/ml peptide completely blocked
SHP-2 association with SHPS-1 in response to IGF-I without
blocking SHPS-1 phosphorylation (Figure 4B). Furthermore,
addition of the peptide impaired both Shc recruitment to
SHPS-1 and Shc phosphorylation in response to IGF-I (Fig-
ure 4, B and C). After IGF-I stimulation for 5 min, there was
a 3.6  0.9 (n  3, p  0.05)-fold increase in p52Shc
phosphorylation and 3.0  0.5 (n  3, p  0.05)-fold
increase in p52Shc binding to SHPS-1 in the control cul-
tures. However, 1.2  0.2- (p  NS) and 1.1  0.1 (p 
NS)-fold increases were induced by IGF-I in cultures ex-
posed to the peptide. These effects were not observed
when a control peptide that contained a phospho-tyrosine
motif within p85 was incubated with the cells (our un-
published data). These results suggest that SHP-2 recruit-
ment is necessary for Shc phosphorylation by regulating
the recruitment of Shc to SHPS-1. Further analysis by
sequential immunoprecipitation of Shc indicated that
SHP-2 can be coimmunoprecipitated with Shc, and this
association was enhanced upon IGF-I stimulation (5.6 
0.9-fold increase over basal, n  3, p  0.05) (Figure 4D).
Preincubation of the cells with a peptide that contains a
proline-rich region of Shc reduced the increased SHP-2
association with Shc that occurred in response to IGF-I
(1.4  0.7-fold increase, p  NS). Addition of the peptide
did not significantly change the basal association of Shc
and SHP-2 (p  NS). Because SHP-2 does not contain a
SH3 domain, these results indicate that SHP-2 does not
directly bind to Shc and a third protein is involved in
mediating SHP-2/Shc association.
Figure 2. IGF-I–dependent Shc phosphorylation and sustained MAP
kinase activation are impaired in cells expressing the 3-FF mutant. (A)
Confluent cultures were serum starved overnight and lysed in modi-
fied RIPA. 3 phosphorylation was evaluated by immunoprecipitating
with an anti-3 antibody followed by immunoblotting with p-Tyr.
Thirty microliters of cell lysate was analyzed by immunoblotting with
anti-3 antiserum for detection of 3 protein. (B) Confluent cultures
were serum depleted overnight, and the cells were stimulated with
IGF-I for the indicated times. Samples from control and 3-FF cells
were immunoprecipitated with anti-Shc and immunoblotted with anti-
p-Tyr to detect phosphorylation of Shc (top). Densitometric units of
phospho-Shc divided by the total Shc protein levels (n  3) are 240 
29, 835  178, 762  135, and 637  43 in vector cells and 107  24,
126  83, 116  12, and 103  74 in 3-FF cells. Grb2 association was
detected by immunoblotting with anti-Grb2 after Shc immunoprecipi-
tation (middle). Densitometric units of Grb2 divided by the total Shc
protein levels (n  3) are 311  74, 636  99, 603  95, 642  112, 119 
49, 134  77, 146  55, and 138  37. The levels of Shc protein were
assessed by immunoprecipitation followed by immunoblotting with
anti-Shc antibody (bottom). (C) Phosphorylation of IRS-1 and its bind-
ing to Grb2 were analyzed under the same conditions by using immu-
noprecipitation with anti-IRS-1 antibody and immunoblotting with
p-Tyr (top) or anti-Grb2 antibodies (middle). Densitometric units nor-
malized by the total IRS-1 protein levels (n  3) are 134  25, 973  58,
577  45, 563  69, 133  22, 889  66, 888  136, and 960  165 for
phospho-IRS-1 and 366  34, 726  59, 403  105, 468  66, 327  30,
689  138, 832  200, and 748  240 for Grb2. IRS-1 protein level was
analyzed by immunoprecipitation and immunoblotting with an anti-
IRS-1 antibody (bottom). (D) Representative immunoblots of phos-
phorylated Erk1,2 (top) and total Erk1,2 protein (bottom) are shown.
Thirty microliters of cell lysate from basal and IGF-I–treated samples
was analyzed by immunoblotting as described in Materials and Meth-
ods. (E) The phosphorylation of Erk1,2 normalized for total Erks was
quantified using scanning densitometry. Each point is the mean 
SEM of three separate experiments. *p  0.05 when cells expressing
3-FF are compared with vector-transfected control group.
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Shc Binding to SHPS-1 Is Required for Shc
Phosphorylation
Because in all our previous experiments we had disrupted
both SHP-2 and Shc binding to SHPS-1, we wished to de-
termine whether we could inhibit Shc binding to SHPS-1 but
retain SHP-2 binding and whether this would alter Shc
phosphorylation in response to IGF-I. SMC cultures were
exposed to the cell-permeable peptide that contained a pro-
Figure 3. The cytoplasmic domain of SHPS-1 is required for IGF-I–dependent Shc phosphorylation. (A) Nontransfected confluent cultures
were serum starved overnight and then stimulated with IGF-I for 5 min. The cells were lysed in the modified RIPA buffer. Sequential
immunoprecipitation was performed using an anti-3 antibody followed by immunoblotting with an anti-Shc antibody or anti-3 antibody.
Thirty microliters of cell lysate was used to analyze the residual 3 after the first “A” and second round “B” of immunoprecipitation by direct
immunoblotting with the anti-3 antibody. (B) Top, expression of endogenous SHPS-1 and HA-labeled SHPS-1/WT (S/WT) was assessed
by immunoblotting with anti-SHPS-1 antibody by using 30 l of cell lysates. Bottom, SMC cultures expressing HA-SHPS-1/WT or
SHPS-1/-CD were biotinylated with 0.5 mg/ml biotin as described in Materials and Methods. The cells were lysed, and the lysates were
immunoprecipitated with anti-HA antibody. The blots were subsequently probed with avidin-horseradish peroxidase to detect surface
expression of HA-SHPS-1/WT or HA-SHPS-1/-CD. (C) SMCs expressing HA-SHPS-1/-CD or HA-SHPS-1/WT were serum starved
overnight, and IGF-I was added for indicated times before lysing the cells. Prior to immunoprecipitation, the lysates were incubated with
protein-A beads for 1 h at 4°C. The samples were centrifuged for 5 min at 14,000  g, then the supernatants were incubated with 1:330 anti-Shc
antibody, and the blots were immunoblotted with anti-HA to detect the association between HA-SHPS-1/WT and Shc. (D) Cells that were
expressing SHPS-1/WT or SHPS-1/-CD were serum starved overnight and stimulated with IGF-I for indicated times. Shc phosphorylation
and its association with Grb2 were detected by immunoprecipitating with an anti-Shc antibody and immunoblotting with anti p-Tyr (top)
or anti-Grb2 antisera (middle). The Shc protein level shown in the lower panel was detected by reprobing the membrane with a monoclonal
anti-Shc antibody. The values for phospho-Shc divided by the amount of Shc that was immunoprecipitated are 484  65, 896  24, 1068 
200, 374  38, 425  130, 300  51, 252  56, and 236  8 (n  3). The values for Shc-associated Grb2 are 228  17, 625  52, 654  98, 255 
50, 255  93, 217  46, 185  28, and 229  79. (E) Thirty microliters of cell lysate from the same experiment was used for detection of
phospho-Erk1,2 by immunoblotting with anti-phospho-Erk1,2 antibody. The blots were stripped and reprobed with anti-Erk1,2 antibodies.
(F) The phosphorylation of Erk1,2 normalized by the protein level was quantified using scanning densitometry. Each point represents the
mean  SEM of three separate experiments. **p  0.01 when SHPS-1/-CD cells were compared with cells expressing SHPS-1/WT.
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line-rich region of Shc that had been shown to disrupt Shc/
SHP-2 association (Figure 4D). In the presence of this pep-
tide, Shc binding to SHPS-1 was impaired. IGF-I induced
Shc and SHPS-1 association was reduced by 67.3  7.5% at
5 min (n  3, p  0.01) and by 70.4  11.4% at 10 min (n 
3, p  0.05) after exposure to the peptide (Figure 5A).
Addition of the peptide did not significantly change basal
Shc and SHPS-1 association (p  NS) but was associated
with a decrease of both Shc phosphorylation (61.5  8.2%
reduction compared with control cultures, n  3, p  0.05)
(Figure 5B) and MAP kinase activation (71.3  5.2% reduc-
tion, n  3, p  0.01) after IGF-I stimulation for 10 min
(Figure 5C). Addition of the peptide also decreased IGF-I–
induced Shc phosphorylation at 5 min (62.9  10.7% reduc-
tion n  3, p  0.05), but it did not induce a significant
reduction in phosphorylation of Erk1,2 after IGF-I stimula-
tion for 5 min. This is consistent with our finding that
IGF-I–induced Shc phosphorylation is responsible for sus-
tained MAP kinase activation. To control for a nonspecific
effect, a control peptide that contains the proline-rich region
of a nonrelated protein, DOK1, was used. This peptide did
not inhibit Shc association with SHPS-1, and IGF-I–depen-
dent phosphorylation of Shc and Erk1,2 was stimulated to
levels that were similar to cultures not exposed to this pep-
tide (our unpublished data). To determine whether the effect
was specific for Shc, SHP-2 binding to SHPS-1 was assessed.
In the presence of the blocking peptide SHP-2 binding to
SHPS-1 increased after IGF-I to a level that was comparable
with control cultures (Figure 5A). Because SHP-2 contains a
proline-rich region that has been shown to be required for its
association with c-Src (Walter et al., 1999), we also tested the
effects of Shc proline peptide on SHP-2/c-Src association.
Our results demonstrated that SHP-2/Src association was
not disrupted by peptide incubation (our unpublished data).
The necessity of the polyproline domain in Shc for SHPS-1
association was confirmed using the cells expressing the Shc
mutant with the four proline substitutions (Shc-4A) (Figure
5D). To exclude the possibility of detection of endogenous
Shc binding to SHPS-1, we used SMCs expressing either
HA-Shc-WT or HA-Shc-4A and immunoprecipitated cell ly-
sates with the anti-HA antibody. Our results indicated that
only wild-type Shc but not Shc-4A mutant was associated
Figure 4. Recruitment of SHP-2 to SHPS-1 is necessary for Shc association with SHPS-1 in response to IGF-I. (A) Cells expressing
pMEP4-vector or pMEP4-3FF were serum depleted overnight before IGF-I was added for the indicated times. The cell lysates were
immunoprecipitated with anti-Shc antibody and immunoblotted with anti-SHPS-1 polyclonal antibody. Shc protein level was verified by
subsequent immunoblotting with anti-Shc antibody. Densitometric units of SHPS-1 that is associated with Shc normalized by the total Shc
protein levels are 409  106, 1193  210, 644  158, 128  32, 172  48, and 160  25. (B) Confluent cultures were serum starved overnight
and incubated with or without the SHPS-1 cell-permeable peptide (20 g/ml) for 1 h. IGF-I was added for indicated times. The cell lysates
were immunoprecipitated with anti-SHPS-1 antibody followed by immunoblotting for SHP-2 (first panel) and phosphorylated SHPS-1
(second panel). Densitometric units of SHP-2 normalized by the total SHPS-1 protein levels are 215  45, 978  195, 339  120, 233  67, 207 
104, and 308  123. The units for phospho-SHPS-1 divided by total SHPS-1 are 289  153, 1031  227, 764  126, 254  90, 964  149, and
777  145. Association of Shc and SHPS-1 was evaluated by immunoprecipitating with anti-SHPS-1 antibody and immunoblotting with
monoclonal anti-Shc antibody (third panel). The densitometric units of Shc that is associated with SHPS-1 are 369  82, 1046  165, 436 
133, 323  57, 387  127, and 206  59. SHPS-1 protein level was quantified by reprobing the membrane with anti-SHPS-1 antibody (fourth
panel). (C) IGF-I–mediated Shc phosphorylation was analyzed by immunoprecipitating with a polyclonal anti-Shc antibody then immuno-
blotting with anti-p-Tyr. Normalized densitometric units of Shc phosphorylation are 284  71, 941  213, 788  170, 192  62, 212  81, and
190  84. Shc protein was detected by reprobing the membrane with a monoclonal anti-Shc antibody. (D) The association of SHP-2 and Shc
was analyzed by sequential immunoprecipitation of Shc followed by immunoblotting for SHP-2 in the absence or in the presence of the Shc
proline peptide (top). Densitometric units of SHP-2 normalized by immunoprecipitated Shc protein are 86  23, 461  112, 130  27, and
175  53. Levels of Shc protein are shown (bottom).
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with SHPS-1 upon IGF-I stimulation (Figure 5D), indicating
that the presence of the polyproline sequence within Shc
was required for SHPS-1 association. The results demon-
strate that in SMCs Shc binding to SHPS-1 is absolutely
required for Shc phosphorylation and therefore downstream
signaling and that this interaction requires the Shc polypro-
line domain.
DISCUSSION
Ligand occupancy of the V3 integrin and tyrosine phos-
phorylation of the 3 subunit regulate the recruitment and
transfer of SHP-2 to the plasma membrane and to SHPS-1. In
SMCs, these transfers are required for IGF-I–stimulated cell
migration and proliferation (Zheng and Clemmons, 1998;
Maile et al., 2001; Ling et al., 2003). This study focused on the
role of SHPS-1 in providing a site of localization for both
SHP-2 and Shc and on how their binding to SHPS-1 regu-
lates IGF-I–dependent activation of the MAP kinase path-
way. Our results show that sustained MAP kinase activation
in response to IGF-I is mediated by Shc phosphorylation and
that this activation step requires recruitment of Shc to
SHPS-1. SHP-2 binding to SHPS-1 is also necessary, al-
though not sufficient for IGF-I–dependent Shc phosphory-
lation. These results support a model in which SHPS-1 func-
tions as a scaffolding protein to recruit key signaling
molecules that are required for an optimal mitogenic re-
sponse to IGF-I.
Integrin activation is required for sustained MAP kinase
activation in response to serum (Lin et al., 1997; Eliceiri et al.,
1998; Kim et al., 2003). Previous studies have shown that
cells must be attached to extracellular matrix proteins to
exhibit sustained Erk activation after growth factor stimula-
tion (Lin et al., 1997; Renshaw et al., 1997; Eliceiri et al., 1998;
Kim et al., 2003). Consistent with those observations, this
study shows that in SMCs, 3 phosphorylation is required
for sustained Erk phosphorylation in response to IGF-I, sup-
porting the conclusion that in pSMC, integrin activation may
be considered as a basal requirement for adequate MAP
kinase induction after IGF-I stimulation. This study also
shows that Shc phosphorylation is required for sustained
MAP kinase activation and that SHP-2 association with Shc
is necessary for Shc phosphorylation. Together with our
previous findings (Ling et al., 2003), these results support a
model in which V3 ligand occupancy and subsequent 3
phosphorylation regulate SHP-2 recruitment to SHPS-1 and
thus its availability for recruitment of Shc to SHPS-1, which
is required for Shc phosphorylation.
Both IRS-1 and Shc are adaptor proteins that undergo
tyrosine phosphorylation upon growth factor stimulation.
Phosphorylation of IRS-1 is dispensable for IGF-I–induced
Erk activation in fibroblasts (Bruning et al., 1997), but it has
been linked to activation of the PI-3 kinase pathway, which
has been shown to contribute to differentiated cellular func-
tions such as cell migration or membrane ruffling (Kim et al.,
1998; Zheng and Clemmons, 1998; Bartucci et al., 2001). In
contrast, Shc-mediated signaling is thought to be a major
component of growth factor-dependent MAP kinase activa-
tion (Ravichandran, 2001; Sasaoka et al., 2001). In a variety of
cell lines, including 3T3-L1 preadipocytes (Boney et al.,
2000), CHO cells (Chow et al., 1998; Sasaoka et al., 2001), and
neuroblastoma cells (Kim et al., 1998), IGF-I–dependent mi-
togenesis requires Shc phosphorylation and its subsequent
binding to Grb2. Expression of a dominant negative Shc
mutant that cannot be phosphorylated in neuroblastoma
cells led to decreased mitogenic signaling and defective
neurite outgrowth (Kim et al., 1998). Our results show that
overexpression of the Shc-3F mutant in SMCs leads to im-
paired phosphorylation of Erks and decreased cell prolifer-
ation. Therefore, Shc phosphorylation and its association
Figure 5. The proline-rich region of Shc mediates its association
with SHPS-1. (A) Confluent cultures were serum starved overnight
and incubated with or without the cell-permeable Shc proline-
peptide (20 g/ml) for 1 h. IGF-I was added for indicated times. The
association of Shc with SHPS-1 was detected by immunoprecipitat-
ing with an anti-SHPS-1 antibody followed by immunoblotting with
anti-Shc antiserum (top). Densitometric units of Shc normalized by
the total SHPS-1 protein levels are 180  70, 915  68, 970  308,
303  105, 305  92, and 240  12. SHP-2 association with SHPS-1
and SHPS-1 protein was detected by reprobing the membrane with
anti-SHP-2 (bottom) and anti-SHPS-1 antibodies (middle), respec-
tively. Normalized units of SHP-2 are 307  70, 1032  236, 877 
111, 295  112, 802  147, and 843  189. (B) Phosphorylation of Shc
in response to IGF-I was analyzed by immunoprecipitation of Shc
and immunoblotting with anti-p-Tyr. The scanning units of phos-
pho-Shc divided by total immunoprecipitated Shc are 309  37,
982  158, 785  192, 269  137, 382  147, and 296  67. The
amount of immunoprecipitated Shc protein is shown (bottom). (C)
IGF-I–dependent phosphorylation of Erk1,2 was evaluated using 30
l of cell lysate and immunoblotting with anti-phospho-Erk1,2.
Equal amounts of total Erk protein were loaded as indicated by
immunoblotting the membrane with anti-Erk1,2 antiserum. Nor-
malized units of phospho-Erk are 138  45, 594  177, 1296  21,
112  24, 389  107, and 372  66. (D) Top, SMCs expressing either
an Shc-WT or an Shc mutant that had four prolines changed to
alanines (Shc-4A) were used to evaluate HA-Shc/SHPS-1 association.
Middle, levels of Shc that were immunoprecipitated by an anti-HA
antibody. Bottom, levels of HA-Shc-WT or HA-Shc-4A by direct im-
munoblotting of 30 l of cell lysate with the anti-HA antibody.
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with Grb2 are essential for IGF-I–dependent MAP kinase
activation and mitogenesis in SMCs. In addition, cells ex-
pressing the 3-FF mutant that exhibited impaired IGF-I–
dependent DNA synthesis (Ling et al., 2003) also showed
impaired Shc but not IRS-1 phosphorylation in response to
IGF-I. Together with our previous studies, we conclude that
in SMCs, Shc but not IRS-1 phosphorylation is required for
sustained MAP kinase activation, whereas IGF-I–dependent
phosphorylation of IRS-1 is mainly responsible for activation
of the PI-3 kinase pathway that mediates IGF-I stimulation
of SMC migration (Zheng and Clemmons, 1998; Inagaki et
al., 2000).
Several studies have analyzed Shc recruitment and local-
ization in response to growth factor stimulation. After EGF
stimulation, Shc distribution is changed from a diffuse cyto-
solic pattern to discrete localization along the plasma mem-
brane (Sato et al., 2000), suggesting that Shc has to be re-
cruited to a specific cellular compartment to be
phosphorylated (Di Guglielmo et al., 1994; Sato et al., 2000).
The requirement of compartmentalization of Shc also has
been documented in studies using IGF-I. When Shc was
localized in caveolae, IGF-I induced Shc phosphorylation,
Grb2 association, and Ras activation, which led to induction
of MAP kinase activation (Biedi et al., 2003). These studies
suggest that recruitment of Shc to a membrane protein com-
plex may facilitate its subsequent phosphorylation. The
IIb3 integrin can facilitate formation of such a complex by
directly recruiting Shc to the phosphorylated 3 cytoplasmic
domain, thereby leading to Shc phosphorylation (Cowan et
al., 2000; Phillips et al., 2001a). However, we were not able to
coimmunoprecipitate Shc with 3 integrin, suggesting that
in stably attached, primary SMC cultures a membrane pro-
tein other than 3 functions to localize Shc in the membrane
fraction. Although phosphorylation of 3 does not directly
recruit Shc, our results show that by regulating SHP-2 trans-
fer to SHPS-1, 3 phosphorylation contributes to Shc recruit-
ment and that this provides a link between ligand occu-
pancy of the V3 integrin and IGF-I signaling.
Prior observations prompted us to focus on the membrane
protein SHPS-1 as a candidate for Shc localization. SHPS-1
functions as a scaffold protein that is capable of binding to
various proteins and recruiting them to the plasma mem-
brane (Oshima et al., 2002). These proteins include protein
tyrosine phosphatases (Kharitonenkov et al., 1997; Takada et
al., 1998), Src family kinases (Gresham et al., 2000), focal
adhesion kinase–related cytosolic kinase, PYK2 (Timms et
al., 1999), and Janus kinase 2 as well as adapter proteins, e.g.,
Grb2 (Kharitonenkov et al., 1997). In addition, both the ex-
tracellular and cytoplasmic domains of SHPS-1 are impor-
tant determinants of intracellular signaling responses that
regulate both mitogenesis and cell migration (Kharitonen-
kov et al., 1997; Inagaki et al., 2000; Motegi et al., 2003; Sato et
al., 2003). Our results support a role for SHPS-1 in providing
a scaffold for Shc localization and clearly indicate that in
SMCs Shc binding to SHPS-1 is required for IGF-I–depen-
dent Shc phosphorylation and subsequent downstream sig-
naling. These results are in contrast to the results from
Kasuga’s group showing that in immortalized fibroblasts
derived from mice expressing a mutant SHPS-1 that lacks
the cytoplasmic domain, IGF-I–induced phosphorylation of
Erk1,2 was not impaired (Inagaki et al., 2000). It is likely that
in fibroblasts the role of SHP-2 in growth factor-dependent
Erk pathways might be mediated by a docking protein other
than SHPS-1, as suggested by the authors.
SHPS-1 also serves as a substrate for phosphatase SHP-2.
The binding of SHP-2 to tyrosine-phosphorylated SHPS-1
activates its catalytic activity, and this activation has been
shown to be required for sustained MAP kinase phosphor-
ylation in response to cell attachment (Oh et al., 1999) as well
as insulin- or serum-stimulated mitogenic responses (Nogu-
chi et al., 1994; Fujioka et al., 1996; Zhang et al., 2002; Ling et
al., 2003). In pSMCs, failure to transfer SHP-2 to SHPS-1
correlates with impairment of sustained Erk phosphoryla-
tion, decreased DNA synthesis, and cell proliferation in
response to IGF-I (Ling et al., 2003; Maile et al., 2003). This
study extends those findings to show that IGF-I induces Shc
association with SHP-2 and that this association is required
for Shc association with SHPS-1 and for Shc phosphoryla-
tion. Even though SHP-2 also associates with Shc, their
increased association in response to IGF-I seems to be indi-
rect because it requires an intact polyproline region of Shc
and SHP-2 has no SH3 domain. Therefore, these results
indicate that a third protein that contains an SH3 domain is
probably involved in mediating the IGF-I stimulation in-
crease in Shc binding to SHP-2. In this paradigm, IGF-I
stimulation may act to enhance binding of SHP-2 to an SH-3
domain containing linker protein and thereby facilitate Shc
recruitment to SHPS-1 and its subsequent phosphorylation.
In our studies, we used a blocking peptide approach to
evaluate the role of SHP-2/SHPS-1 association in mediating
IGF-I–induced mitogenic signaling. Although we did not
use phosphorylated SHPS-1 peptides, because this may de-
crease cell permeability, our results indicated that after a
30-min incubation with cells, the peptides undergo tyrosine
phosphorylation. Previous studies indicated that microinjec-
tion of protected phosphopeptides can inhibit growth factor-
mediated DNA synthesis, whereas nonprotected peptides
did not due to its vulnerability to intracellular phosphatase
(Xiao et al., 1994). Because several factors such as expression
of receptor tyrosine kinases, levels of phosphatases (Lam-
mers et al., 1993) and oxidative status (Meng et al., 2002) can
influence intracellular phosphatase activities, it is possible
that dephosphorylation of peptides occurs at a much slower
rate in our system compared with theirs, thereby prolonging
the half-life of the phosphorylated peptide that functions to
block SHP-2 binding to SHPS-1.
In summary, we conclude that IGF-I–dependent Shc
phosphorylation is required for sustained MAP kinase acti-
vation and cell proliferation. Recruitment of SHP-2 and Shc
to SHPS-1 in response to IGF-I are both required for Shc
phosphorylation and therefore necessary for mediating IGF-
I–dependent mitogenic signaling in SMCs.
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